Brief: Relmada Therapeutics To Discontinue The Reliance Ii And Relight Phase 3 Studies Of Rel-1017
09/12/2024 12:35
Dec 9 (Reuters) - Relmada Therapeutics RLMD.O :
* RELMADA THERAPEUTICS TO DISCONTINUE THE RELIANCE II AND
RELIGHT
PHASE 3 STUDIES OF REL-1017
* RELMADA THERAPEUTICS INC: WILL CONTINUE TO ADVANCE PHASE 1
STUDY
OF REL-P11, AN INVESTIGATIONAL AGENT FOR TREATMENT OF METABOLIC
DISEASE
* RELMADA THERAPEUTICS INC: TO EXPLORE STRATEGIC
ALTERNATIVES
Source text: ID:nGNX8RxPyd
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million